InterCure (NASDAQ:INCR) Shares Down 6.6% – Should You Sell?

InterCure Ltd. (NASDAQ:INCR)’s stock price fell 6.6% during trading on Tuesday . The stock traded as low as $0.9895 and last traded at $0.99. 537,181 shares traded hands during mid-day trading, an increase of 833% from the average session volume of 57,585 shares. The stock had previously closed at $1.06.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InterCure in a report on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, InterCure currently has an average rating of “Sell”.

InterCure Stock Down 6.6%

The firm’s fifty day moving average price is $1.33 and its 200-day moving average price is $1.48. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.85 and a quick ratio of 1.09.

InterCure (NASDAQ:INCR) last posted its earnings results on Wednesday, October 8th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $19.25 million during the quarter.

InterCure Company Profile

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.